| Pharmaceutical Information |
| Drug Name |
Liraglutide |
| Drug ID |
BADD_D01298 |
| Description |
Victoza contains liraglutide, a synthetic analog of human glucagon-like peptide-1(GLP-1) and acts as a GLP-1 receptor agonist[Label,A6932]. Liraglutide is 97% homologous to native human GLP-1 by substituting arginine for lysine at position 34[A6932]. Liraglutide is made by attaching a C-16 fatty acid (palmitic acid) with a glutamic acid spacer on the remaining lysine residue at position 26 of the peptide precursor[A6932]. Liraglutide was granted FDA approval on Januray 25, 2010[L6070]. |
| Indications and Usage |
Liraglutide is indicated in combination with diet and exercise to improve glycemic control in patients 10 years and older with type 2 diabetes mellitus[Label,L6718]. It is also indicated to reduce the risk of major adverse cardiovascular events in patients with type 2 diabetes mellitus as well as cardiovascular disease[Label]. |
| Marketing Status |
approved |
| ATC Code |
A10BJ02 |
| DrugBank ID |
DB06655
|
| KEGG ID |
D06404
|
| MeSH ID |
D000069450
|
| PubChem ID |
16134956
|
| TTD Drug ID |
D03GOI
|
| NDC Product Code |
52221-122; 71052-126; 66558-0193; 50090-4503; 76177-118; 0420-9006; 41524-0011; 50090-2853; 65129-1375; 14403-0009; 69766-034; 0169-4060; 70155-003; 71796-022; 0169-2800; 32861-0003 |
| UNII |
839I73S42A
|
| Synonyms |
Liraglutide | Victoza | Saxenda | NN 2211 | 2211, NN | NN2211 | NN-2211 |
|
| Chemical Information |
| Molecular Formula |
C172H265N43O51 |
| CAS Registry Number |
204656-20-2 |
| SMILES |
CCCCCCCCCCCCCCCC(=O)NC(CCC(=O)NCCCCC(C(=O)NC(CCC(=O)O)C(=O)NC(CC1=CC=CC=C1)C(=O)
NC(C(C)CC)C(=O)NC(C)C(=O)NC(CC2=CNC3=CC=CC=C32)C(=O)NC(CC(C)C)C(=O)NC(C(C)C)C(=O
)NC(CCCNC(=N)N)C(=O)NCC(=O)NC(CCCNC(=N)N)C(=O)NCC(=O)O)NC(=O)C(C)NC(=O)C(C)NC(=O
)C(CCC(=O)N)NC(=O)CNC(=O)C(CCC(=O)O)NC(=O)C(CC(C)C)NC(=O)C(CC4=CC=C(C=C4)O)NC(=O
)C(CO)NC(=O)C(CO)NC(=O)C(C(C)C)NC(=O)C(CC(=O)O)NC(=O)C(CO)NC(=O)C(C(C)O)NC(=O)C(
CC5=CC=CC=C5)NC(=O)C(C(C)O)NC(=O)CNC(=O)C(CCC(=O)O)NC(=O)C(C)NC(=O)C(CC6=CN=CN6)
N)C(=O)O |
| Chemical Structure |
|
|
| ADRs Induced by Drug |
|
|
*The priority for ADR severity classification is based on FAERS assessment, followed by the most severe level in CTCAE rating. If neither is available, it will be displayed as 'Not available'.
**The 'Not Available' level is hidden by default and can be restored by clicking on the legend twice..
|
|
|
